The Journal of clinical psychiatryJan 1, 1997

Creating New Medicines for Depression

Psychedelic Science Weekly Brief ↗PubMed ↗

Updated Mar 25, 2026

Abstract

A large number of novel antidepressants are currently undergoing clinical evaluation with dual mechanisms of action on various neurotransmitter receptors.

Many antidepressants target multiple neurotransmitter receptors, including serotonin and noradrenergic systems.
Mirtazapine exemplifies this dual action by disinhibiting serotonin and norepinephrine neurotransmission.
Mirtazapine's antagonistic properties at serotonin-2 and serotonin-3 receptors may reduce side effects associated with traditional SSRIs.
The concept of 'designer polypharmacy' aims to combine pharmacologic principles to enhance effectiveness and tolerability of new antidepressants.

Simplified

A large number of novel antidepressants acting on a variety of neurotransmitter receptors are currently undergoing clinical evaluation. Most agents have a dual mechanism of action on two or more neurotransmitter receptors, including two serotonin receptors, two noradrenergic receptors, or a combination of serotonin and noradrenergic mechanisms. The most recently approved agent, mirtazapine, is an example of this approach of simultaneously targeting both the serotonergic and noradrenergic systems. Specifically, mirtazapine's alpha 2 antagonism disinhibits both serotonin and norepinephrine neurotransmission while its serotonin-2 and serotonin-3 antagonist properties reduce the side effects normally associated with nonselective serotonin receptor activation by serotonin selective reuptake inhibitors (SSRIs). This approach of "designer polypharmacy" applies principles of rational pharmacologic combinations to enhance efficacy and improve tolerability of the new and emerging antidepressants.

Creating New Medicines for Depression

Abstract

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the psychedelic science brief

Abstract

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the psychedelic science brief